Several possible studies
Story checked
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain : ScienceAlert (opens in a new tab)
sciencealert.com · 2026-10-18
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
A New Injection Makes Fat Cells Self-Destruct, And Might Prevent GLP-1 Weight Regain : ScienceAlert
sciencealert.com · 2026-10-18
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedEarly clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off.View evidenceHide evidence
As statedpromising results
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedThe drug, CBL-514, is administered by injection and has been shown to reduce subcutaneous fat; the article says there is also evidence it can reduce visceral fat.View evidenceHide evidence
As statedreduce subcutaneous fat; evidence it can also reduce visceral fat
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedTwo phase 2 clinical trials, CBL-0204 and CBL-0205, involved 107 and 173 participants respectively, and showed that CBL-514 was effective at reducing subcutaneous fat in the majority of volunteers.View evidenceHide evidence
As stated107 and 173 participants; majority of volunteers
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedA subset of 41 participants was analyzed for visceral fat changes; those given CBL-514 for up to 12 weeks had an average visceral-fat reduction of 12.01 percent, while placebo participants had an average visceral-fat increase of 5.68 percent four weeks after their final injection.View evidenceHide evidence
As stated12.01 percent reduction; 5.68 percent increase; 41 participants; up to 12 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedIn animal tests, rats treated with tirzepatide and CBL-514 together lost more weight on average than rats given tirzepatide alone, and they gained less weight when tirzepatide was stopped.View evidenceHide evidence
As statedmore weight on average; less weight when tirzepatide was stopped
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe article says the findings have not been peer-reviewed yet and come from conference presentations and company announcements, so they should be taken with caution for now.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.
Aesthetic Surgery Journal · 2026 · PubMed, Europe PMC, Crossref
Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction
Aesthetic Surgery Journal · 2022 · PubMed, Europe PMC, Crossref
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Aesthetic Surgery Journal · 2025 · PubMed, Europe PMC, Crossref
Fig. 2. Appearance of patient Sh. Before surgery - hyperemia and acne on the back, hair loss on the head, excessive development of subcutaneous fat on the abdomen.
Crossref
Modern and Non-Invasive Methods of Fat Removal.
2023 · Europe PMC